These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 28903946)
1. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice. Lakhia R; Yheskel M; Flaten A; Quittner-Strom EB; Holland WL; Patel V Am J Physiol Renal Physiol; 2018 Jan; 314(1):F122-F131. PubMed ID: 28903946 [TBL] [Abstract][Full Text] [Related]
2. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype. Hashimoto T; Fujita T; Usuda N; Cook W; Qi C; Peters JM; Gonzalez FJ; Yeldandi AV; Rao MS; Reddy JK J Biol Chem; 1999 Jul; 274(27):19228-36. PubMed ID: 10383430 [TBL] [Abstract][Full Text] [Related]
3. Impairment of PPAR Chung KW; Lee EK; Lee MK; Oh GT; Yu BP; Chung HY J Am Soc Nephrol; 2018 Apr; 29(4):1223-1237. PubMed ID: 29440279 [TBL] [Abstract][Full Text] [Related]
4. Fenofibrate, a peroxisome proliferator-activated receptor α ligand, prevents abnormal liver function induced by a fasting-refeeding process. Lee JN; Dutta RK; Kim SG; Lim JY; Kim SJ; Choe SK; Yoo KW; Song SR; Park DS; So HS; Park R Biochem Biophys Res Commun; 2013 Dec; 442(1-2):22-7. PubMed ID: 24211584 [TBL] [Abstract][Full Text] [Related]
5. Ouabain enhances renal cyst growth in a slowly progressive mouse model of autosomal dominant polycystic kidney disease. Trant J; Sanchez G; McDermott JP; Blanco G Am J Physiol Renal Physiol; 2023 Dec; 325(6):F857-F869. PubMed ID: 37823195 [TBL] [Abstract][Full Text] [Related]
6. The role of PPARα in autosomal dominant polycystic kidney disease. Lakhia R Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):432-438. PubMed ID: 32427692 [TBL] [Abstract][Full Text] [Related]
7. Pparα activation stimulates autophagic flux through lipid catabolism-independent route. Zhang YY; Wang JX; Qiao F; Zhang ML; Luo Y; Du ZY Fish Physiol Biochem; 2024 Jun; 50(3):1141-1155. PubMed ID: 38401031 [TBL] [Abstract][Full Text] [Related]
8. A mutant thyroid hormone receptor alpha antagonizes peroxisome proliferator-activated receptor alpha signaling in vivo and impairs fatty acid oxidation. Liu YY; Heymann RS; Moatamed F; Schultz JJ; Sobel D; Brent GA Endocrinology; 2007 Mar; 148(3):1206-17. PubMed ID: 17122078 [TBL] [Abstract][Full Text] [Related]
9. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice. Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105 [TBL] [Abstract][Full Text] [Related]
10. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency. Asai T; Okumura K; Takahashi R; Matsui H; Numaguchi Y; Murakami H; Murakami R; Murohara T Cardiovasc Res; 2006 Jun; 70(3):566-77. PubMed ID: 16546150 [TBL] [Abstract][Full Text] [Related]
11. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation. Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177 [TBL] [Abstract][Full Text] [Related]
12. PPARα activation protects against cholestatic liver injury. Zhao Q; Yang R; Wang J; Hu DD; Li F Sci Rep; 2017 Aug; 7(1):9967. PubMed ID: 28855630 [TBL] [Abstract][Full Text] [Related]
13. Circadian clock disruption and growth of kidney cysts in autosomal dominant polycystic kidney disease. Jamadar A; Ward CJ; Remadevi V; Varghese MM; Pabla NS; Gumz ML; Rao R bioRxiv; 2024 Aug; ():. PubMed ID: 39211074 [TBL] [Abstract][Full Text] [Related]
15. Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging. Kim SM; Lee B; An HJ; Kim DH; Park KC; Noh SG; Chung KW; Lee EK; Kim KM; Kim DH; Kim SJ; Chun P; Lee HJ; Moon HR; Chung HY Oncotarget; 2017 Jul; 8(28):46273-46285. PubMed ID: 28545035 [TBL] [Abstract][Full Text] [Related]
16. Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice. Murru E; Muntoni AL; Manca C; Aroni S; Pistis M; Banni S; Carta G Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614161 [TBL] [Abstract][Full Text] [Related]
17. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007 [TBL] [Abstract][Full Text] [Related]
19. Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal. El Kebbaj Z; Andreoletti P; Mountassif D; Kabine M; Schohn H; Dauça M; Latruffe N; El Kebbaj MS; Cherkaoui-Malki M Endocrinology; 2009 Mar; 150(3):1192-201. PubMed ID: 18948393 [TBL] [Abstract][Full Text] [Related]